This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Impact Therapeutics, Inc.. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Innovations of Hongqiang Fei in Hedgehog Pathway Inhibition
Introduction
Hongqiang Fei is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target the hedgehog signaling pathway. His work is crucial in the fight against various clinical conditions, including cancer.
Latest Patents
Hongqiang Fei holds a patent for his invention titled "N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof." This patent describes novel compounds represented by a specific formula, which are designed to inhibit the hedgehog pathway. The compounds have potential therapeutic applications in treating conditions responsive to hedgehog activity inhibition, such as cancer. He has 1 patent to his name.
Career Highlights
Fei is currently associated with Impact Therapeutics, Inc., where he continues to advance his research in the field. His innovative work has positioned him as a key figure in the development of new therapeutic agents.
Collaborations
He collaborates with esteemed colleagues, including Suixiong Cai and Ye Edward Tian, to further enhance the impact of their research in the pharmaceutical industry.
Conclusion
Hongqiang Fei's contributions to the field of medicinal chemistry, particularly through his patent on hedgehog pathway inhibitors, highlight his role as an influential inventor. His ongoing work at Impact Therapeutics, Inc. continues to pave the way for innovative treatments in cancer therapy.